SPL 0.00% 9.7¢ starpharma holdings limited

Quarterly Report, page-41

  1. 12,902 Posts.
    lightbulb Created with Sketch. 1440
    Good to hear Dep Docetaxel Phase 2 trial dosing of cohort has began in combination
    with nintedanib

    For those that are not aware......Starpharma is conducting 2 parallel studies with dep docetaxel.

    One with Dep Docetaxel alone for several indications and the other in combination with nintedanib focusing on lung cancer
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.